3.74
0.09 (2.47%)
| Previous Close | 3.65 |
| Open | 3.67 |
| Volume | 87,904 |
| Avg. Volume (3M) | 71,649 |
| Market Cap | 59,455,532 |
| Price / Book | 2.69 |
| 52 Weeks Range | |
| Earnings Date | 12 Nov 2025 |
| Diluted EPS (TTM) | -4.24 |
| Total Debt/Equity (MRQ) | 10,265.12% |
| Current Ratio (MRQ) | 0.710 |
| Operating Cash Flow (TTM) | -21.96 M |
| Levered Free Cash Flow (TTM) | -12.03 M |
| Return on Assets (TTM) | -86.72% |
| Return on Equity (TTM) | -853.05% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | PolyPid Ltd. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | -4.5 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | 1.0 |
| Average | -1.13 |
|
PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. Its product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 25.65% |
| % Held by Institutions | 49.51% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Symmetry Peak Management Llc | 30 Jun 2025 | 63,950 |
| Lumbard & Kellner, Llc | 30 Jun 2025 | 38,200 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 13.00 (HC Wainwright & Co., 247.59%) | Buy |
| 13.00 (Craig-Hallum, 247.59%) | Buy | |
| Median | 13.00 (247.59%) | |
| Low | 9.00 (Roth Capital, 140.64%) | Buy |
| Average | 11.67 (212.03%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 3.50 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Roth Capital | 13 Nov 2025 | 9.00 (140.64%) | Buy | 3.58 |
| Craig-Hallum | 14 Aug 2025 | 13.00 (247.59%) | Buy | 3.43 |
| HC Wainwright & Co. | 13 Aug 2025 | 13.00 (247.59%) | Buy | 3.49 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |